A scientific statement has been published by the AHA regarding the relationship between alcohol use and cardiovascular disease.

Acute flares in patients with RA were linked to higher risk for AD/ADRD, but the relationship was not significant.

The FDA has approved Benlysta for SC administration using an autoinjector in patients 5 years of age and older with active LN.

Higher UPF-consumption was linked to worse knee OA outcomes among women, including higher pain scores, worse physical function, and thinner knee cartilage.

A large percentage of patients with SSc screened positive for ARFID, reporting significant GI symptom burden and reduced HRQOL.

Upadacitinib demonstrated greater clinical efficacy and a comparable safety profile to adalimumab for treating RA, regardless of patients’ baseline CV risks.